Literature DB >> 17469109

Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms.

Douglas W Zochodne1.   

Abstract

Diabetes targets the peripheral nervous system with several different patterns of damage and several mechanisms of disease. Diabetic polyneuropathy (DPN) is a common disorder involving a large proportion of diabetic patients, yet its pathophysiology is controversial. Mechanisms considered have included polyol flux, microangiopathy, oxidative stress, abnormal signaling from advanced glycation endproducts and growth factor deficiency. Although some clinical trials have demonstrated modest benefits in disease stabilization or pain therapy in DPN, robust therapy capable of reversing the disease is unavailable. In this review, general aspects of DPN and other diabetic neuropathies are examined, including a summary of recent therapeutic trials. A particular emphasis is placed on the evidence that the neurobiology of DPN reflects a unique yet common and disabling neurodegenerative disorder.

Entities:  

Mesh:

Year:  2007        PMID: 17469109     DOI: 10.1002/mus.20785

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  65 in total

1.  Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Authors:  Lawrence Coppey; Eric Davidson; Bao Lu; Craig Gerard; Mark Yorek
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

2.  In vivo peripheral nervous system insulin signaling.

Authors:  Caleb W Grote; Janelle M Ryals; Douglas E Wright
Journal:  J Peripher Nerv Syst       Date:  2013-09       Impact factor: 3.494

3.  Novel systems for in vivo monitoring and microenvironmental investigations of diabetic neuropathy in a murine model.

Authors:  Sharon Amit; Avraham Yaron
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

Review 4.  Schwann cells as a therapeutic target for peripheral neuropathies.

Authors:  Helmar C Lehmann; Ahmet Höke
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

5.  Restless legs syndrome and diabetic neuropathy.

Authors:  Franco Gemignani; Francesca Brindani; Adriana Marbini
Journal:  Sleep       Date:  2008-03       Impact factor: 5.849

Review 6.  [Diabetic neuropathy].

Authors:  Monika Lechleitner; Heidemarie Abrahamian; Claudia Francesconi; Markus Kofler
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

7.  The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy.

Authors:  Eric Davidson; Lawrence Coppey; Bao Lu; Victor Arballo; Nigel A Calcutt; Craig Gerard; Mark Yorek
Journal:  Exp Diabetes Res       Date:  2010-02-03

8.  Vitamin E supplementation in rats with experimental diabetes mellitus: analysis of myosin-V and nNOS immunoreactive myenteric neurons from terminal ileum.

Authors:  Renata Virginia Fernandes Pereira; Marcílio Hubner de Miranda-Neto; Ivan Domicio da Silva Souza; Jacqueline Nelisis Zanoni
Journal:  J Mol Histol       Date:  2008-10-24       Impact factor: 2.611

9.  Intranasal insulin ameliorates experimental diabetic neuropathy.

Authors:  George Francis; Jose Martinez; Wei Liu; Thuhien Nguyen; Amit Ayer; Jared Fine; Douglas Zochodne; Leah R Hanson; William H Frey; Cory Toth
Journal:  Diabetes       Date:  2009-01-09       Impact factor: 9.461

10.  Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy.

Authors:  James F McGuire; Shefali Rouen; Eric Siegfreid; Douglas E Wright; Rick T Dobrowsky
Journal:  Diabetes       Date:  2009-08-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.